Your browser doesn't support javascript.
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET.
Talarico, Rosaria; Aguilera, Silvia; Alexander, Tobias; Amoura, Zahir; Antunes, Ana M; Arnaud, Laurent; Avcin, Tadej; Beretta, Lorenzo; Bombardieri, Stefano; Burmester, Gerd R; Cannizzo, Sara; Cavagna, Lorenzo; Chaigne, Benjamin; Cornet, Alain; Costedoat-Chalumeau, Nathalie; Doria, Andrea; Ferraris, Alessandro; Fischer-Betz, Rebecca; Fonseca, João E; Frank, Charissa; Gaglioti, Andrea; Galetti, Ilaria; Grunert, Jürgen; Guimarães, Vera; Hachulla, Eric; Houssiau, Frederic; Iaccarino, Luca; Krieg, Thomas; Limper, Marteen; Malfait, Fransiska; Mariette, Xavier; Marinello, Diana; Martin, Thierry; Matthews, Lisa; Matucci-Cerinic, Marco; Meyer, Alain; Montecucco, Carlomaurizio; Mouthon, Luc; Müller-Ladner, Ulf; Rednic, Simona; Romão, Vasco C; Schneider, Matthias; Smith, Vanessa; Sulli, Alberto; Tamirou, Farah; Taruscio, Domenica; Taulaigo, Anna V; Terol, Enrique; Tincani, Angela; Ticciati, Simone.
  • Talarico R; Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Aguilera S; Spanish Association for Antiphospholipid Syndrome (SAF España), Elche, Spain.
  • Alexander T; Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.
  • Amoura Z; Department of Internal Medicine, Hospital Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, French National Referral Center for SLE and APS, Paris, France.
  • Antunes AM; Auto-immune Disease Unit, Hospital de Curry Cabral, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal.
  • Arnaud L; Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Systémiques et Auto-immunes Rares Grand-Est Sud-Ouest (RESO), Strasbourg, France.
  • Avcin T; Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Beretta L; Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
  • Bombardieri S; University of Pisa, Pisa, Italy.
  • Burmester GR; Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.
  • Cannizzo S; Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Cavagna L; Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Chaigne B; Department of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Cornet A; Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies systémiques Autoimmunes Rares d'Ile de France, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France.
  • Costedoat-Chalumeau N; Lupus Europe, Brussels, Belgium.
  • Doria A; Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies systémiques Autoimmunes Rares d'Ile de France, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France.
  • Ferraris A; Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Fischer-Betz R; Medical Genetics Laboratory, Molecular Medicine Department, San Camillo Forlanini Hospital, Sapienza University, Rome, Italy.
  • Fonseca JE; Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Frank C; Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
  • Gaglioti A; Flemish Association for Hereditary Connective Tissue Disorders, Koersel, Belgium.
  • Galetti I; Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Grunert J; Federation of European Scleroderma Associations (FESCA), Milan, Italy.
  • Guimarães V; Deutsche Ehlers-Danlos Initiative e.V., Furth, Germany.
  • Hachulla E; Liga Portuguesa Contra as Doenças Reumáticas, Lisbon, Portugal.
  • Houssiau F; Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest (CERAINO), LIRIC, INSERM, Univ. Lille, CHU Lille, Lille, France.
  • Iaccarino L; Department of Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Krieg T; Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Limper M; Department of Dermatology, Universitätsklinikum, Cologne, Germany.
  • Malfait F; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Mariette X; Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
  • Marinello D; Université Paris-Saclay, INSERM, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes; AP-HP. Université Paris-Saclay, Hôpital Bicêtre, Rheumatology Department, Le Kremlin Bicêtre, Paris, France.
  • Martin T; Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Matthews L; Clinical immunology department, Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Systémiques et Auto-immunes Rares Grand-Est Sud-Ouest (RESO), Strasbourg, France.
  • Matucci-Cerinic M; Relapsing Polychondritis Awareness and Support, Worcester, UK.
  • Meyer A; Division of Rheumatology and Scleroderma Unit, Department of Clinical and Experimental Medicine, AOU Careggi, University of Florence, Florence, Italy.
  • Montecucco C; Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Systémiques et Auto-immunes Rares Grand-Est Sud-Ouest (RESO), Strasbourg, France.
  • Mouthon L; Department of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Müller-Ladner U; Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies systémiques Autoimmunes Rares d'Ile de France, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France.
  • Rednic S; Department of Rheumatology and Clinical Immunology, Kerckhoff Klinik, Justus Liebig University of Giessen, Bad Nauheim, Germany.
  • Romão VC; Department of Rheumatology, Emergency County Teaching Hospital, Cluj-Napoca, Romania.
  • Schneider M; Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
  • Smith V; Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Sulli A; Department of Rheumatology, Ghent University Hospital Department of Internal Medicine, Ghent, Belgium.
  • Tamirou F; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy.
  • Taruscio D; Department of Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Taulaigo AV; National Centre for Rare Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Terol E; Auto-immune Disease Unit, Hospital de Curry Cabral, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal.
  • Tincani A; Directorate-General for Health and Food Safety, European Commission, Brussels, Belgium.
  • Ticciati S; Rheumatology and Clinical Immunology Unit, ASST-Spedali Civili and University of Brescia, Brescia, Italy.
Nat Rev Rheumatol ; 17(3): 177-184, 2021 03.
Article in English | MEDLINE | ID: covidwho-1012684
ABSTRACT
During the COVID-19 pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing for, and limited the routine care of, all other conditions. The impact of this health emergency is particularly relevant in the rare connective tissue diseases (rCTDs) communities, as discussed in this Perspective article by the multi-stakeholder European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). The clinical, organizational and health economic challenges faced by health-care providers, institutions, patients and their families during the SARS-CoV-2 outbreak have demonstrated the importance of ensuring continuity of care in the management of rCTDs, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. The vulnerability of patients with rCTDs needs to be taken into account when planning future health policies, in preparation for not only the post-COVID era, but also any possible new health emergencies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Connective Tissue Diseases / Delivery of Health Care / Pandemics / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Nat Rev Rheumatol Journal subject: Rheumatology Year: 2021 Document Type: Article Affiliation country: S41584-020-00565-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Connective Tissue Diseases / Delivery of Health Care / Pandemics / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Nat Rev Rheumatol Journal subject: Rheumatology Year: 2021 Document Type: Article Affiliation country: S41584-020-00565-z